EYEMATE : Study Highlights Importance of Continual IOP Monitoring for Glaucoma

Currently glaucoma patients are getting (2-6) visits per year in a
doctor’s office. It puts patients at high risk of undetected disease
progression. Clinical study published recently, shows
EYEMATE TM system is safe, reliable and monitor IOP
continuously without regular office visits. The FDA
“Breakthrough Device” approval process has been started, in
preparation for launching it in the USA. The CE-marked
EYEMATE system is now offered in Germany, Switzarland and
the UK. Prof. Kaweh Mansouri, lead author of the study and
ophthalmologist at Clinique de Montchoisi
Lausanne/Switzerland, explains: "Our findings show that
occasional IOP measurements, as are currently done in clinical
practice, poorly reflect actual IOP behavior in patients. These
data underline the importance of continual IOP monitoring for
better management of glaucoma care."

Share - whatsappTelegramEmailFacebookGoogleLinkedInPrintRedditTwitter